House Dems raise issues with ‘atypical’ FDA review process for Alzheimer’s drug

via Health Care https://ift.tt/9dMpI1N The panels began investigating Aduhelm’s approval and pricing in June 2021, just weeks after it won the FDA’s backing despite questions about the drug’s clinical benefit to patients.